Novavax COVID-19 vaccine has 90% efficacy: pivotal trial

The company has also shown that inoculation with coronavirus and influenza vaccines at the same time doesn’t compromise immune response

Novavax’s COVID-19 vaccine has been shown to be highly effective against moderate and severe disease — including in high-risk groups, such as over-65s and those with comorbidities — trial results show.


The long-awaited pivotal phase III data for the recombinant protein subunit vaccine known as NVX-CoV2373, which are not yet published, show an overall efficacy of 90% against the coronavirus, the company has announced.

At the same time, Novavax has published the first